
Survival Analysis

Summary Statistics



Contingency Tables by Mutation Status					
Characteristic [†]	Mutation Status				
	No Mutation, N = 277	Mutation, N = 28	p-value ²		
Age			<0.001		
Over 50	201 (73%)	10 (36%)			
Under 50	76 (27%)	18 (64%)			
Estrogen Status			0.002		
Negative	50 (18%)	12 (43%)			
Positive	86 (31%)	2 (7.1%)			
Unknown	141 (51%)	14 (50%)			
Tumor Stage			0.13		
Stage 1	204 (74%)	18 (64%)			
Stage 2	60 (22%)	6 (21%)			
Unknown	13 (4.7%)	4 (14%)			
Lymph Node Invovlement	,	,	0.044		
>0	94 (34%)	16 (57%)			
0	170 (61%)	11 (39%)			
Unknown	13 (4.7%)	1 (3.6%)			
Histology	13 (4.770)	1 (3.070)	0.074		
• • • • • • • • • • • • • • • • • • • •	227 (929/)	27 (069/)	0.074		
Infiltrating ductal	227 (82%)	27 (96%)			
Medullary	4 (1.4%)	1 (3.6%)			
Other ductal	23 (8.3%)	0 (0%)			
Infiltrating lobular	23 (8.3%)	0 (0%)			
Chemotherapy			0.058		
Not Had	175 (63%)	12 (43%)			
Had	78 (28%)	14 (50%)			
Unknown	24 (8.7%)	2 (7.1%)			
Tamoxifen			0.2		
Not Had	96 (35%)	6 (21%)			
Had	147 (53%)	20 (71%)			
Unknown	34 (12%)	2 (7.1%)			
Dead to Breast Cancer (DOBC)			0.040		
No Event	241 (87%)	20 (71%)			
Event	35 (13%)	8 (29%)			
Unknown	1	0			
Ipsilateral Recurrence (IBTR)			0.7		
No Event	254 (92%)	25 (89%)			
Event	23 (8.3%)	3 (11%)			
Distant Recurrence (DR)			0.040		
No Event	228 (82%)	18 (64%)			
Event	49 (18%)	10 (36%)			
Contralteral Recurrence (CR)	, ,	, ,	0.011		
No Event	244 (88%)	19 (68%)			
Event	27 (9.7%)	8 (29%)			
Unknown	6 (2.2%)	1 (3.6%)			
Disease Free Survival (AD)	U (2.2/0)	1 (0.070)	<0.001		
	106 (710/)	10 (269/)	<0.001		
No Event	196 (71%)	10 (36%)			
Event	81 (29%)	18 (64%)	0.40		
Overall Survival	040 (700)	40 (040)	0.13		
No Event	218 (79%)	18 (64%)			
Event	59 (21%)	10 (36%)			

¹ Statistics presented: n (%) ² Statistical tests performed: chi-square test of independence; Fisher's exact test

Customized Contingency Tables by Age				
	Age			
Characteristic ¹ -		p-value ²		

Mutation Status		010.00, 2	• · · · · · · · · · · · · · · · · · · ·	
Mutation	Mutation Status			<0.001
Negative	No Mutation	201 (95%)	76 (81%)	
Negative	Mutation	10 (4.7%)	18 (19%)	
Positive	Estrogen Status			<0.001
Tumor Stage Stage 1 161 (76%) 61 (65%) Stage 2 44 (21%) 22 (23%) Unknown 6 (2.8%) 111 (12%) Lymph Node Invovlement >0 63 (30%) 47 (50%) 0 135 (64%) 46 (49%) Unknown 13 (6.2%) 11 (1.1%) Histology 0,9 Infiltrating ductal 173 (82%) 81 (86%) Medullary 4 (1.9%) 1 (1.1%) Other ductal 17 (8.1%) 6 (6.4%) Infiltrating lobular 17 (8.1%) 6 (6.4%) Infiltrating lobular 17 (8.1%) 6 (6.4%) Unknown 16 (7.6%) 10 (11%) Tamoxifen	Negative	33 (16%)	29 (31%)	
Tumor Stage 0.005 Stage 1 161 (76%) 61 (65%) Stage 2 44 (21%) 22 (23%) Unknown 6 (2.8%) 11 (12%) Lymph Node Invovlement 0.001 >0 63 (30%) 47 (50%) Unknown 135 (64%) 46 (49%) Unknown 13 (6.2%) 1 (1.1%) Histology 0.9 Infiltrating ductal 173 (82%) 81 (86%) Medullary 4 (1.9%) 1 (1.1%) 0.9 Other ductal 17 (8.1%) 6 (6.4%) 0.001 Other ductal 17 (8.1%) 6 (6.4%) 0.001 Other ductal 17 (8.1%) 6 (6.4%) 0.001 Infiltrating lobular 17 (8.1%) 6 (6.4%) 0.001 Chemotherapy <0.001	Positive	73 (35%)	15 (16%)	
Stage 1	Unknown	105 (50%)	50 (53%)	
Stage 2 44 (21%) 22 (23%) Unknown 6 (2.8%) 11 (12%) Lymph Node Invovlement 0.001 >0 63 (30%) 47 (50%) 0 135 (64%) 46 (49%) Unknown 13 (6.2%) 1 (1.1%) Histology 0.9 Inflitrating ductal 173 (82%) 81 (86%) Medullary 4 (1.9%) 1 (1.1%) Other ductal 17 (8.1%) 6 (6.4%) Inflitrating lobular 17 (8.1%) 6 (6.4%) Inflitrating lobular 17 (8.1%) 6 (6.4%) Not Had 152 (72%) 35 (37%) Had 43 (20%) 49 (52%) Unknown 16 (7.6%) 10 (11%) Tamoxifen <0.001	Tumor Stage			0.005
Lymph Node Invovement 0.001 >0 63 (30%) 47 (50%) 0 135 (64%) 46 (49%) Unknown 13 (6.2%) 1 (1.1%) Histology 0.9 Infiltrating ductal 173 (82%) 81 (86%) Medullary 4 (1.9%) 1 (1.1%) Other ductal 17 (8.1%) 6 (6.4%) Infiltrating lobular 17 (8.1%) 6 (6.4%) Chemotherapy <0.001	Stage 1	161 (76%)	61 (65%)	
Lymph Node Invovlement 0.001	Stage 2	44 (21%)	22 (23%)	
>0 63 (30%) 47 (50%) 0 135 (64%) 46 (49%) Unknown 13 (6.2%) 1 (1.1%) Histology 0,9 Infiltrating ductal 173 (82%) 81 (86%) Medullary 4 (1.9%) 1 (1.1%) Other ductal 17 (8.1%) 6 (6.4%) Infiltrating lobular 17 (8.1%) 6 (6.4%) Chemotherapy <0.001 Not Had 152 (72%) 35 (37%) Had 43 (20%) 49 (52%) Unknown 16 (7.6%) 10 (11%) Tamoxifen <0.001 Not Had 90 (43%) 12 (13%) Had 100 (47%) 67 (71%) Unknown 21 (10.0%) 15 (16%) Dead to Breast Cancer (DOBC) No Event 186 (89%) 75 (80%) Event 24 (11%) 19 (20%) Unknown 19 (34%) 81 (86%) Event 198 (94%) 81 (86%) Event 198 (94%) 81 (86%) Event 13 (6.2%) 13 (14%) Distant Recurrence (IBTR) No Event 176 (83%) 70 (74%) Event 35 (17%) 24 (26%) Contralteral Recurrence (CR) No Event 183 (87%) 80 (85%) Event 21 (10.0%) 14 (15%) Unknown 7 (3.3%) 0 (0%) Disease Free Survival (AD) No Event 151 (72%) 55 (59%) Event 60 (28%) 39 (41%) Overall Survival No Event 151 (72%) 55 (59%) Event 60 (28%) 39 (41%)	Unknown	6 (2.8%)	11 (12%)	
0 135 (64%) 46 (49%) Unknown 13 (6.2%) 1 (1.1%) Histology 0.9 Infilitrating ductal 173 (82%) 81 (86%) Medullary 4 (1.9%) 1 (1.1%) Other ductal 17 (8.1%) 6 (6.4%) Infilitrating lobular 17 (8.1%) 6 (6.4%) Infilitrating lobular 17 (8.1%) 6 (6.4%) Chemotherapy < <0.001 Not Had 152 (72%) 35 (37%) Had 43 (20%) 49 (52%) Unknown 16 (7.6%) 10 (11%) Tamoxifen < <0.001 Not Had 90 (43%) 12 (13%) Had 100 (47%) 67 (71%) Unknown 21 (10.0%) 15 (16%) Dead to Breast Cancer (DOBC) No Event 186 (89%) 75 (80%) Event 24 (11%) 19 (20%) Unknown 1 3 0 0.046 No Event 198 (94%) 81 (86%) Event 198 (94%) 81 (86%) Event 13 (6.2%) 13 (14%) Distant Recurrence (IBTR) No Event 176 (83%) 70 (74%) Event 35 (17%) 24 (26%) Contralteral Recurrence (CR) No Event 183 (87%) 80 (85%) Event 21 (10.0%) 14 (15%) Unknown 7 (3.3%) 0 (0%) Disease Free Survival (AD) No Event 151 (72%) 55 (59%) Event 60 (28%) 39 (41%) Overall Survival No Event 162 (77%) 74 (79%)	Lymph Node Invovlement			0.001
Unknown 13 (6.2%) 1 (1.1%) Histology 0.9 Infiltrating ductal 173 (82%) 81 (86%) Medullary 4 (1.9%) 1 (1.1%) Other ductal 17 (8.1%) 6 (6.4%) Infiltrating lobular 17 (8.1%) 6 (6.4%) Chemotherapy < <0.001 Not Had 152 (72%) 35 (37%) Had 43 (20%) 49 (52%) Unknown 16 (7.6%) 10 (11%) Tamoxifen < <0.001 Not Had 90 (43%) 12 (13%) Had 100 (47%) 67 (71%) Unknown 21 (10.0%) 15 (16%) Dead to Breast Cancer (DOBC) No Event 186 (89%) 75 (80%) Event 24 (11%) 19 (20%) Unknown 1 0 Ipsilateral Recurrence (IBTR) No Event 198 (94%) 81 (86%) Event 13 (6.2%) 13 (14%) Distant Recurrence (CR) No Event 176 (83%) 70 (74%) Event 35 (17%) 24 (26%) Contralteral Recurrence (CR) No Event 183 (87%) 80 (85%) Event 21 (10.0%) 14 (15%) Unknown 7 (3.3%) 0 (0%) Disease Free Survival (AD) No Event 151 (72%) 55 (59%) Event 60 (28%) 39 (41%) Overall Survival No Event Incompany 74 (79%)	>0	63 (30%)	47 (50%)	
Histology	0	135 (64%)	46 (49%)	
Infiltrating ductal 173 (82%) 81 (86%) Medullary 4 (1.9%) 1 (1.1%) Other ductal 17 (8.1%) 6 (6.4%) Infiltrating lobular 17 (8.1%) 6 (6.4%) Chemotherapy < <0.001 Not Had 152 (72%) 35 (37%) Had 43 (20%) 49 (52%) Unknown 16 (7.6%) 10 (11%) Tamoxifen < <0.001 Not Had 90 (43%) 12 (13%) Had 100 (47%) 67 (71%) Unknown 21 (10.0%) 15 (16%) Dead to Breast Cancer (DOBC) 0.064 No Event 186 (89%) 75 (80%) Event 24 (11%) 19 (20%) Unknown 1 0 Ipsilateral Recurrence (IBTR) 0.046 No Event 198 (94%) 81 (86%) Event 13 (6.2%) 13 (14%) Distant Recurrence (CR) 0.10 No Event 183 (87%) 80 (85%) Event 21 (10.0%) 14 (15%) Unknown 7 (3.3%) 0 (0%) Disease Free Survival (AD) 0.88 No Event 151 (72%) 55 (59%) Event 60 (28%) 39 (41%) Overall Survival No Event 162 (77%) 74 (79%)	Unknown	13 (6.2%)	1 (1.1%)	
Medullary 4 (1.9%) 1 (1.1%) Other ductal 17 (8.1%) 6 (6.4%) Infiltrating lobular 17 (8.1%) 6 (6.4%) Chemotherapy <0.001	Histology			0.9
Other ductal 17 (8.1%) 6 (6.4%) Infiltrating lobular 17 (8.1%) 6 (6.4%) Chemotherapy <0.001	Infiltrating ductal	173 (82%)	81 (86%)	
Infiltrating lobular	Medullary	4 (1.9%)	1 (1.1%)	
Chemotherapy <0.001	Other ductal	17 (8.1%)	6 (6.4%)	
Not Had	Infiltrating lobular	17 (8.1%)	6 (6.4%)	
Had 43 (20%) 49 (52%) Unknown 16 (7.6%) 10 (11%) Tamoxifen < 0.001 Not Had 90 (43%) 12 (13%) Had 100 (47%) 67 (71%) Unknown 21 (10.0%) 15 (16%) Dead to Breast Cancer (DOBC) 0.064 No Event 186 (89%) 75 (80%) Event 24 (11%) 19 (20%) Unknown 1 0 0 Ipsilateral Recurrence (IBTR) 0.046 No Event 198 (94%) 81 (86%) Event 13 (6.2%) 13 (14%) Distant Recurrence (DR) 0.10 No Event 176 (83%) 70 (74%) Event 35 (17%) 24 (26%) Contralteral Recurrence (CR) No Event 183 (87%) 80 (85%) Event 21 (10.0%) 14 (15%) Unknown 7 (3.3%) 0 (0%) Disease Free Survival (AD) No Event 151 (72%) 55 (59%) Event 60 (28%) 39 (41%) Overall Survival No Event 162 (77%) 74 (79%)	Chemotherapy			<0.001
Unknown 16 (7.6%) 10 (11%) Tamoxifen < 0.001 Not Had 90 (43%) 12 (13%) Had 100 (47%) 67 (71%) Unknown 21 (10.0%) 15 (16%) Dead to Breast Cancer (DOBC) No Event 186 (89%) 75 (80%) Event 24 (11%) 19 (20%) Unknown 1 0 Ipsilateral Recurrence (IBTR) No Event 198 (94%) 81 (86%) Event 13 (6.2%) 13 (14%) Distant Recurrence (DR) No Event 176 (83%) 70 (74%) Event 35 (17%) 24 (26%) Contralteral Recurrence (CR) No Event 183 (87%) 80 (85%) Event 21 (10.0%) 14 (15%) Unknown 7 (3.3%) 0 (0%) Disease Free Survival (AD) No Event 151 (72%) 55 (59%) Event 60 (28%) 39 (41%) Overall Survival No Event 162 (77%) 74 (79%)	Not Had	152 (72%)	35 (37%)	
Tamoxifen < 0.001 Not Had 90 (43%) 12 (13%) Had 100 (47%) 67 (71%) Unknown 21 (10.0%) 15 (16%) Dead to Breast Cancer (DOBC) No Event 186 (89%) 75 (80%) Event 24 (11%) 19 (20%) Unknown 1 0 Ipsilateral Recurrence (IBTR) No Event 198 (94%) 81 (86%) Event 13 (6.2%) 13 (14%) Distant Recurrence (DR) No Event 176 (83%) 70 (74%) Event 35 (17%) 24 (26%) Contralteral Recurrence (CR) No Event 183 (87%) 80 (85%) Event 21 (10.0%) 14 (15%) Unknown 7 (3.3%) 0 (0%) Disease Free Survival (AD) No Event 151 (72%) 55 (59%) Event 60 (28%) 39 (41%) Overall Survival No Event 162 (77%) 74 (79%)	Had	43 (20%)	49 (52%)	
Not Had 90 (43%) 12 (13%) Had 100 (47%) 67 (71%) Unknown 21 (10.0%) 15 (16%) Dead to Breast Cancer (DOBC) 0.064 No Event 186 (89%) 75 (80%) Event 24 (11%) 19 (20%) Unknown 1 0 Ipsilateral Recurrence (IBTR) 0.046 No Event 198 (94%) 81 (86%) Event 13 (6.2%) 13 (14%) Distant Recurrence (DR) 176 (83%) 70 (74%) Event 35 (17%) 24 (26%) Contralteral Recurrence (CR) 0.10 No Event 183 (87%) 80 (85%) Event 21 (10.0%) 14 (15%) Unknown 7 (3.3%) 0 (0%) Disease Free Survival (AD) 55 (59%) Event 60 (28%) 39 (41%) Overall Survival No Event 162 (77%) 74 (79%)	Unknown	16 (7.6%)	10 (11%)	
Had 100 (47%) 67 (71%) Unknown 21 (10.0%) 15 (16%) Dead to Breast Cancer (DOBC) 0.064 No Event 186 (89%) 75 (80%) Event 24 (11%) 19 (20%) Unknown 1 0 Ipsilateral Recurrence (IBTR) 0.046 No Event 198 (94%) 81 (86%) Event 13 (6.2%) 13 (14%) Distant Recurrence (DR) 176 (83%) 70 (74%) Event 35 (17%) 24 (26%) Contralteral Recurrence (CR) 0.10 No Event 183 (87%) 80 (85%) Event 21 (10.0%) 14 (15%) Unknown 7 (3.3%) 0 (0%) Disease Free Survival (AD) 0.034 No Event 151 (72%) 55 (59%) Event 60 (28%) 39 (41%) Overall Survival No Event 162 (77%) 74 (79%)	Tamoxifen			<0.001
Unknown 21 (10.0%) 15 (16%) Dead to Breast Cancer (DOBC) 0.064 No Event 186 (89%) 75 (80%) Event 24 (11%) 19 (20%) Unknown 1 0 Ipsilateral Recurrence (IBTR) 0.046 No Event 198 (94%) 81 (86%) Event 13 (6.2%) 13 (14%) Distant Recurrence (DR) 0.10 No Event 176 (83%) 70 (74%) Event 35 (17%) 24 (26%) Contralteral Recurrence (CR) 0.10 No Event 183 (87%) 80 (85%) Event 21 (10.0%) 14 (15%) Unknown 7 (3.3%) 0 (0%) Disease Free Survival (AD) No Event 151 (72%) 55 (59%) Event 60 (28%) 39 (41%) Overall Survival No Event 162 (77%) 74 (79%)	Not Had	90 (43%)	12 (13%)	
Dead to Breast Cancer (DOBC) 0.064 No Event 186 (89%) 75 (80%) Event 24 (11%) 19 (20%) Unknown 1 0 Ipsilateral Recurrence (IBTR) 0.046 No Event 198 (94%) 81 (86%) Event 13 (6.2%) 13 (14%) Distant Recurrence (DR) 0.10 No Event 176 (83%) 70 (74%) Event 35 (17%) 24 (26%) Contralteral Recurrence (CR) 0.10 No Event 183 (87%) 80 (85%) Event 21 (10.0%) 14 (15%) Unknown 7 (3.3%) 0 (0%) Disease Free Survival (AD) 0.034 No Event 151 (72%) 55 (59%) Event 60 (28%) 39 (41%) Overall Survival 162 (77%) 74 (79%)	Had	100 (47%)	67 (71%)	
No Event 186 (89%) 75 (80%) Event 24 (11%) 19 (20%) Unknown 1 0 Ipsilateral Recurrence (IBTR) 0.046 No Event 198 (94%) 81 (86%) Event 13 (6.2%) 13 (14%) Distant Recurrence (DR) 0.10 No Event 176 (83%) 70 (74%) Event 35 (17%) 24 (26%) Contralteral Recurrence (CR) 0.10 No Event 183 (87%) 80 (85%) Event 21 (10.0%) 14 (15%) Unknown 7 (3.3%) 0 (0%) Disease Free Survival (AD) 0.034 No Event 151 (72%) 55 (59%) Event 60 (28%) 39 (41%) Overall Survival 162 (77%) 74 (79%)	Unknown	21 (10.0%)	15 (16%)	
Event 24 (11%) 19 (20%) Unknown 1 0 Ipsilateral Recurrence (IBTR) 0.046 No Event 198 (94%) 81 (86%) Event 13 (6.2%) 13 (14%) Distant Recurrence (DR) 0.10 No Event 176 (83%) 70 (74%) Event 35 (17%) 24 (26%) Contralteral Recurrence (CR) 0.10 No Event 183 (87%) 80 (85%) Event 21 (10.0%) 14 (15%) Unknown 7 (3.3%) 0 (0%) Disease Free Survival (AD) 0.034 No Event 151 (72%) 55 (59%) Event 60 (28%) 39 (41%) Overall Survival No Event 162 (77%) 74 (79%)	Dead to Breast Cancer (DOBC)			0.064
Unknown 1 0 Ipsilateral Recurrence (IBTR) 0.046 No Event 198 (94%) 81 (86%) Event 13 (6.2%) 13 (14%) Distant Recurrence (DR) 0.10 No Event 176 (83%) 70 (74%) Event 35 (17%) 24 (26%) Contralteral Recurrence (CR) 0.10 No Event 183 (87%) 80 (85%) Event 21 (10.0%) 14 (15%) Unknown 7 (3.3%) 0 (0%) Disease Free Survival (AD) 0.034 No Event 151 (72%) 55 (59%) Event 60 (28%) 39 (41%) Overall Survival 0.8 No Event 162 (77%) 74 (79%)	No Event	186 (89%)	75 (80%)	
Ipsilateral Recurrence (IBTR)	Event	24 (11%)	19 (20%)	
No Event 198 (94%) 81 (86%) Event 13 (6.2%) 13 (14%) Distant Recurrence (DR) 0.10 No Event 176 (83%) 70 (74%) Event 35 (17%) 24 (26%) Contralteral Recurrence (CR) 0.10 No Event 183 (87%) 80 (85%) Event 21 (10.0%) 14 (15%) Unknown 7 (3.3%) 0 (0%) Disease Free Survival (AD) 0.034 No Event 151 (72%) 55 (59%) Event 60 (28%) 39 (41%) Overall Survival No Event 162 (77%) 74 (79%)	Unknown	1	0	
Event 13 (6.2%) 13 (14%) Distant Recurrence (DR) 0.10 No Event 176 (83%) 70 (74%) Event 35 (17%) 24 (26%) Contralteral Recurrence (CR) 0.10 No Event 183 (87%) 80 (85%) Event 21 (10.0%) 14 (15%) Unknown 7 (3.3%) 0 (0%) Disease Free Survival (AD) 0.034 No Event 151 (72%) 55 (59%) Event 60 (28%) 39 (41%) Overall Survival No Event 162 (77%) 74 (79%)	Ipsilateral Recurrence (IBTR)			0.046
Distant Recurrence (DR) 0.10 No Event 176 (83%) 70 (74%) Event 35 (17%) 24 (26%) Contralteral Recurrence (CR) 0.10 No Event 183 (87%) 80 (85%) Event 21 (10.0%) 14 (15%) Unknown 7 (3.3%) 0 (0%) Disease Free Survival (AD) 0.034 No Event 151 (72%) 55 (59%) Event 60 (28%) 39 (41%) Overall Survival 0.8 No Event 162 (77%) 74 (79%)	No Event	198 (94%)	81 (86%)	
No Event 176 (83%) 70 (74%) Event 35 (17%) 24 (26%) Contralteral Recurrence (CR) 0.10 No Event 183 (87%) 80 (85%) Event 21 (10.0%) 14 (15%) Unknown 7 (3.3%) 0 (0%) Disease Free Survival (AD) 0.034 No Event 151 (72%) 55 (59%) Event 60 (28%) 39 (41%) Overall Survival No Event 162 (77%) 74 (79%)	Event	13 (6.2%)	13 (14%)	
Event 35 (17%) 24 (26%) Contralteral Recurrence (CR) 0.10 No Event 183 (87%) 80 (85%) Event 21 (10.0%) 14 (15%) Unknown 7 (3.3%) 0 (0%) Disease Free Survival (AD) 0.034 No Event 151 (72%) 55 (59%) Event 60 (28%) 39 (41%) Overall Survival 0.8 No Event 162 (77%) 74 (79%)	Distant Recurrence (DR)			0.10
Contralteral Recurrence (CR) 0.10 No Event 183 (87%) 80 (85%) Event 21 (10.0%) 14 (15%) Unknown 7 (3.3%) 0 (0%) Disease Free Survival (AD) 0.034 No Event 151 (72%) 55 (59%) Event 60 (28%) 39 (41%) Overall Survival 0.8 No Event 162 (77%) 74 (79%)	No Event	176 (83%)	70 (74%)	
No Event 183 (87%) 80 (85%) Event 21 (10.0%) 14 (15%) Unknown 7 (3.3%) 0 (0%) Disease Free Survival (AD) 0.034 No Event 151 (72%) 55 (59%) Event 60 (28%) 39 (41%) Overall Survival 0.8 No Event 162 (77%) 74 (79%)	Event	35 (17%)	24 (26%)	
Event 21 (10.0%) 14 (15%) Unknown 7 (3.3%) 0 (0%) Disease Free Survival (AD) 0.034 No Event 151 (72%) 55 (59%) Event 60 (28%) 39 (41%) Overall Survival No Event 162 (77%) 74 (79%)	Contralteral Recurrence (CR)			0.10
Unknown 7 (3.3%) 0 (0%) Disease Free Survival (AD) 0.034 No Event 151 (72%) 55 (59%) Event 60 (28%) 39 (41%) Overall Survival 0.8 No Event 162 (77%) 74 (79%)	No Event	183 (87%)	80 (85%)	
Disease Free Survival (AD) 0.034 No Event 151 (72%) 55 (59%) Event 60 (28%) 39 (41%) Overall Survival 0.8 No Event 162 (77%) 74 (79%)	Event	21 (10.0%)	14 (15%)	
No Event 151 (72%) 55 (59%) Event 60 (28%) 39 (41%) Overall Survival 0.8 No Event 162 (77%) 74 (79%)	Unknown	7 (3.3%)	0 (0%)	
Event 60 (28%) 39 (41%) Overall Survival 0.8 No Event 162 (77%) 74 (79%)	Disease Free Survival (AD)			0.034
Overall Survival 0.8 No Event 162 (77%) 74 (79%)	No Event	151 (72%)	55 (59%)	
No Event 162 (77%) 74 (79%)	Event	60 (28%)	39 (41%)	
	Overall Survival			8.0
Event 49 (23%) 20 (21%)	No Event	` ,	74 (79%)	
	Event	49 (23%)	20 (21%)	

¹ Statistics presented: n (%) ² Statistical tests performed: chi-square test of independence; Fisher's exact test

Barplot by Mutation Status and Mutation Status

